Fundamental Analysis of ANI Pharmaceuticals Inc - Growth / Value Index
ANIP - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.272
Book Value in last 3 years is trending up
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 34.42 | 59.52 | 395.07 % | |
| Price to Book | 2.72 | 2.44 | -99.92 % | 2.64 |
| Price to Sales | 2.24 | 2.30 | -27.28 % | |
| Enterprise Value to EBITDA Multiple | 9.05 | 6.78 | -30.31 % |
ANIP - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Net profit has jumped from negative to positive
Reasonable Dividend Yield of 4.44 %
Annual Net Profit in last 3 years is trending up
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
EBITDA is continuously increasing for last 3 Years
Steady Growth in EPS for last four quarters
Low Earning Yield of 2.70 %
In the last three years, the company has given poor Net Margin
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 8.18 | 4.34 | 100.03 % | 3.63 |
| Return On Asset | 3.89 | 2.08 | 100.03 % | 1.79 |
| Net Profit Margin | 6.52 | 3.86 | 124.65 % | 11.93 |
| Operating Profit Margin | 10.07 | 9.65 | 186.52 % | 10.95 |
| EBITDA Margin | 28.86 | 35.83 | -14.17 % | 21.64 |
Highlights
| Market Cap | 1287.67 M |
| Enterprise Value | 1352.22 M |
| Price/Book TTM | 2.72 |
| Outstanding Share | 20961.60 K |
| Float/ Outstanding Share | 74.55% |
| Dividend Yield | 4.44 % |
Share Holding
Guru Numbers
| Price/Graham No | 1.93 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 7.00 |
| Altman Z Score | 3.06 |
| Sloan Ratio | -0.111 |
| Peter Lynch Fair Value | 36.66 |
ANIP - Growth Highlights
Growth Analysis
STRONG JUMP IN NET SALE : YoY growth
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Tsr Growth Index - Very Poor Score of 18.93
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 517460 K | 53.87 % | 4.39 % |
| Gross Profit | 405516 K | 174.11 % | 44.11 % |
| EBITDA | 149356 K | 32.07 % | 38.83 % |
| Net Profit | 33742.00 K | 137.92 % | 1320.09 % |
| EPS | 1.78 | 133.89 % | NA |
ANIP - Stability Highlights
Stability Analysis
Altman Z Score of 3.19 suggests good Stability
Debt to equity ratio has decreased and is lowest in last five years
Decreasing debt with Increasing revenue
Interest Coverage of -4.26
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.660 | -99.93 % | 0.632 |
| Cash Ratio | 1.52 | 213.40 % | |
| Quick Ratio | 2.81 | 16.91 % | 3.12 |
| Shareholders Equity | 47.85 | 15.94 % | |
| Debt to EBITDA | 1.64 | -24.28 % |
Historical Valuation Ratios of ANI Pharmaceuticals Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of ANI Pharmaceuticals Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of ANI Pharmaceuticals Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of ANI Pharmaceuticals Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)